Standard Life Aberdeen plc Purchases 9,888 Shares of Stryker Co. (SYK)

Standard Life Aberdeen plc grew its position in shares of Stryker Co. (NYSE:SYK) by 10.9% in the third quarter, Holdings Channel reports. The fund owned 100,776 shares of the medical technology company’s stock after acquiring an additional 9,888 shares during the period. Standard Life Aberdeen plc’s holdings in Stryker were worth $17,907,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Winch Advisory Services LLC boosted its holdings in shares of Stryker by 12.1% in the 3rd quarter. Winch Advisory Services LLC now owns 15,509 shares of the medical technology company’s stock valued at $2,756,000 after buying an additional 1,673 shares during the last quarter. AMP Capital Investors Ltd boosted its holdings in shares of Stryker by 10.5% in the 3rd quarter. AMP Capital Investors Ltd now owns 133,515 shares of the medical technology company’s stock valued at $23,371,000 after buying an additional 12,719 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Stryker by 10.7% in the 3rd quarter. Blair William & Co. IL now owns 544,256 shares of the medical technology company’s stock valued at $96,703,000 after buying an additional 52,480 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Stryker by 55.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,225 shares of the medical technology company’s stock valued at $5,193,000 after buying an additional 10,400 shares during the last quarter. Finally, Richard Bernstein Advisors LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $3,884,000. 74.72% of the stock is owned by hedge funds and other institutional investors.

SYK stock opened at $172.25 on Thursday. The company has a current ratio of 1.91, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The firm has a market cap of $64.45 billion, a price-to-earnings ratio of 26.54, a PEG ratio of 2.36 and a beta of 0.66. Stryker Co. has a fifty-two week low of $146.80 and a fifty-two week high of $179.84.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.01. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%. As a group, equities analysts expect that Stryker Co. will post 7.28 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 31st. Shareholders of record on Monday, December 31st will be given a dividend of $0.52 per share. This is a boost from Stryker’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a yield of 1.21%. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Stryker from a “buy” rating to a “hold” rating in a research note on Monday. JPMorgan Chase & Co. increased their price target on Stryker to $200.00 and gave the company an “overweight” rating in a research note on Thursday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research note on Tuesday, September 11th. BTIG Research restated a “buy” rating and issued a $187.00 price target on shares of Stryker in a research note on Wednesday, September 12th. Finally, Oppenheimer set a $170.00 price target on Stryker and gave the company a “hold” rating in a research note on Friday, November 9th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Stryker presently has an average rating of “Buy” and an average price target of $182.45.

In other Stryker news, VP M Kathryn Fink sold 415 shares of the stock in a transaction on Monday, November 5th. The stock was sold at an average price of $166.56, for a total transaction of $69,122.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn S. Boehnlein sold 750 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $178.17, for a total value of $133,627.50. Following the transaction, the chief financial officer now owns 2,785 shares in the company, valued at approximately $496,203.45. The disclosure for this sale can be found here. 7.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/12/06/standard-life-aberdeen-plc-purchases-9888-shares-of-stryker-co-syk.html.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: S&P 500 Index

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply